IASO Bio's In Vivo CAR-T: A Game Changer for Oncology?
You ever feel like you're watching history happen right in front of you? That's the vibe with IASO Bio's latest move in the realm of oncology. This outfit just scored a major victory, getting China's NMPA and the U.S. FDA to greenlight their IASO208, a CD20-targeting in vivo CAR-T therapy. It's not every day you see a company land dual regulatory nods like...
Continue Reading